Clinical Trials Browser

Phase 3 × INDUSTRY × Epirubicin × Clear all

NCT07441460 2026-03-02

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

Phase 3 Not yet recruiting

Resectable HER2-positive Breast Cancer

NCT07424287 2026-02-20

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

Phase 3 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06112379 2025-12-17

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Phase 3 Active not recruiting

Breast Neoplasms

NCT01358877 2025-11-28

APHINITY

Phase 3 Completed

4,804 enrolled 45 charts 1 FDA

Breast Neoplasms

NCT03036488 2025-10-29

MK-3475-522

Phase 3 Completed

1,174 enrolled 1 FDA

Triple Negative Breast Neoplasms

NCT03725059 2025-07-11

KEYNOTE-756

Phase 3 Active not recruiting

Breast Neoplasms

NCT03013504 2024-11-06

TROIKA

Phase 3 Completed

Breast Neoplasms

NCT04490993 2022-02-22

ACCRUE

Phase 3 Unknown

Non-Muscle Invasive Bladder Neoplasms

NCT04736394 2022-02-22

ASCERTAIN

Phase 3 Unknown

Non-Muscle Invasive Bladder Neoplasms

NCT05121350 2022-02-18

A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma

Phase 3 Unknown

Sarcoma

NCT03556358 2022-01-14

Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer

Phase 3 Completed

809 enrolled 14 charts

Breast Neoplasms

NCT04301739 2020-03-12

to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)

Phase 3 Not yet recruiting

Triple Negative Breast Neoplasms

NCT00950300 2018-01-23

A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

Phase 3 Completed

596 enrolled 31 charts 1 FDA

Breast Neoplasms

NCT01697072 2016-02-09

RILOMET-1

Phase 3 Terminated

Gastrointestinal

Stomach Neoplasms

NCT00140075 2011-05-26

Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer

Phase 3 Completed

Adenocarcinoma